Cansino Biologics Inc.

This study tests a new vaccine (PCV24) designed to protect against 24 types of pneumococcal bacteria, which can cause pneumonia, meningitis, and ear infections. The trial includes 854 healthy people aged 2 months and older, split into two phases to check safety and immune respons…

This study follows 100 infants who received a pneumococcal vaccine in an earlier trial. Researchers will take a small blood sample to measure antibody levels one and two years after vaccination. The goal is to see how long protection against pneumococcal infections lasts. No new …